Shenzhu Guanxin Recipe Granules () for Improving Exercise Tolerance in Patients with Stable Angina (SERIES Trial): A Protocol of Multicenter, Randomized, Double-Blind, Placebo Parallel Controlled Clinical Trial.
Shenzhu Guanxin Recipe
coronary microcirculation
exercise tolerance
randomized controlled trial
stable angina
trial protocol
Journal
Chinese journal of integrative medicine
ISSN: 1993-0402
Titre abrégé: Chin J Integr Med
Pays: China
ID NLM: 101181180
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
accepted:
19
05
2016
pubmed:
18
10
2018
medline:
7
6
2019
entrez:
18
10
2018
Statut:
ppublish
Résumé
Many patients with chronic angina experience anginal episodes despite successful recanalization, antianginal and antiischemic medications. Empirical observations suggested that Shenzhu Guanxin Recipe Granules (, SGR), a Chinese herbal compound, exerted potential impacts on increased treadmill exercise performance and angina relieve. However, there has been no systematic study to clarify the impact of SGR on exercise tolerance in patients with stable angina. The SERIES (ShEnzhu guanxin Recipe for Improving Exercise tolerance in patients with Stable angina) trial is designed to determine the effects of SGR on exercise duration, electrocardiographic (ECG) evidence of myocardial ischemia, and incidence of major adverse cardiac events (MACE) in stable anginal patients. A total of 184 eligible patients with stable angina will be randomly assigned to receive placebo or SGR (10 g/day for 12 weeks) in a 1:1 ratio. The primary outcome will be the change from baseline in total exercise tolerance duration, time to onset of angina and ECG ischemia during exercise treadmill testing performed over a 12-week study period. The secondary outcome will include ECG measures, the occurrence and composite of MACE and the Seattle Angina Questionnaire score. Moreover, the coronary microcirculation will be evaluated to explore the possible effects in response to treatment of SGR. After the procedure, all participants will be followed up by interview at 3 and 6 months, enquiring about any cardiac events, hospitalizations, cardiac functional level and medication usage. Additionally, the occurrence of adverse events will be evaluated at each follow-up. This study may provide novel evidence on the efficacy of SGR in improving exercise tolerance and potentially reducing clinical adverse events. (Trial registration No. ChiCTR-TRC-14004504).
Sections du résumé
BACKGROUND
BACKGROUND
Many patients with chronic angina experience anginal episodes despite successful recanalization, antianginal and antiischemic medications. Empirical observations suggested that Shenzhu Guanxin Recipe Granules (, SGR), a Chinese herbal compound, exerted potential impacts on increased treadmill exercise performance and angina relieve. However, there has been no systematic study to clarify the impact of SGR on exercise tolerance in patients with stable angina. The SERIES (ShEnzhu guanxin Recipe for Improving Exercise tolerance in patients with Stable angina) trial is designed to determine the effects of SGR on exercise duration, electrocardiographic (ECG) evidence of myocardial ischemia, and incidence of major adverse cardiac events (MACE) in stable anginal patients.
METHODS
METHODS
A total of 184 eligible patients with stable angina will be randomly assigned to receive placebo or SGR (10 g/day for 12 weeks) in a 1:1 ratio. The primary outcome will be the change from baseline in total exercise tolerance duration, time to onset of angina and ECG ischemia during exercise treadmill testing performed over a 12-week study period. The secondary outcome will include ECG measures, the occurrence and composite of MACE and the Seattle Angina Questionnaire score. Moreover, the coronary microcirculation will be evaluated to explore the possible effects in response to treatment of SGR. After the procedure, all participants will be followed up by interview at 3 and 6 months, enquiring about any cardiac events, hospitalizations, cardiac functional level and medication usage. Additionally, the occurrence of adverse events will be evaluated at each follow-up.
DISCUSSION
CONCLUSIONS
This study may provide novel evidence on the efficacy of SGR in improving exercise tolerance and potentially reducing clinical adverse events. (Trial registration No. ChiCTR-TRC-14004504).
Identifiants
pubmed: 30328569
doi: 10.1007/s11655-018-3017-z
pii: 10.1007/s11655-018-3017-z
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Placebos
0
shenzhu guanxin
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
96-102Références
Am J Cardiol. 2001 Jun 15;87(12):1430-2
pubmed: 11397374
J Am Coll Cardiol. 2002 Oct 16;40(8):1531-40
pubmed: 12392846
Am Heart J. 2002 Nov;144(5):826-33
pubmed: 12422151
J Cardiovasc Pharmacol Ther. 2004 Sep;9 Suppl 1:S11-29; quiz S98-9
pubmed: 15378129
Circ J. 2005 Aug;69(8):934-9
pubmed: 16041162
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Jan;26(1):28-32
pubmed: 16466168
Eur Heart J. 2006 Jun;27(11):1341-81
pubmed: 16735367
Am J Cardiol. 1992 Jan 1;69(1):84-9
pubmed: 1729872
J Am Coll Cardiol. 2007 Dec 4;50(23):2264-74
pubmed: 18061078
Vasc Health Risk Manag. 2010 Sep 07;6:749-74
pubmed: 20859545
Evid Based Complement Alternat Med. 2012;2012:417387
pubmed: 22536282
J Am Coll Cardiol. 2012 Oct 16;60(16):1581-98
pubmed: 22958960
JACC Cardiovasc Imaging. 2013 Jan;6(1):1-12
pubmed: 23219414
Chin J Integr Med. 2012 Dec;18(12):891-6
pubmed: 23238996
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
J Am Soc Echocardiogr. 2013 Nov;26(11):1282-9
pubmed: 24044977
Eur Heart J. 2014 Apr;35(14):895-903
pubmed: 24071762
J Am Soc Echocardiogr. 2014 May;27(5):520-30
pubmed: 24637056
Complement Ther Med. 2014 Aug;22(4):814-25
pubmed: 25146085
Int J Cardiol. 2015 Mar 1;182:329-33
pubmed: 25585378
Chin J Integr Med. 2015 Jun;21(6):408-16
pubmed: 26063318
N Engl J Med. 2016 Mar 24;374(12):1167-76
pubmed: 27007960
BMC Complement Altern Med. 2016 Nov 8;16(1):447
pubmed: 27825334
J Am Coll Cardiol. 1995 Feb;25(2):333-41
pubmed: 7829785